title: Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).
abstract: Forty-six children with juvenile myelomonocytic leukemia (JMML) diagnosed between 1978 and 1993 in 12 centers were retrospectively studied. There is no evidence that any conventional treatment influences the long-term evolution of JMML. Among 28 patients treated without bone marrow transplantation (BMT), 26 died (median survival: 17 months), two are alive, one in complete remission (CR) after intensive chemotherapy. Allogenic BMT is the best treatment: 18 patients underwent BMT, 11 are in CR (at 9, 15, 22, 25, 41, 45, 49, 53, 66, 90 and 108 months). Conditioning regimens using chemotherapy alone may cure some patients (3/6) occasionally despite autologous reconstitution (1/3); if relapse occurs, a second BMT may be curative (2/3). Among the 12 patients conditioned immediately with TBI, six are in CR, one is in relapse, five died (one of them in durable autologus CR from Schwannoma). It is our opinion that splenectomy is of therapeutic value and seems not to have influenced the incidence of infections complications. We found no argument in favor of intensive chemotherapy before conditioning. Results with HLA-matched unrelated donors are satisfactory. One patient relapsed at 4 months after an unrelated BMT and entered a new CR after discontinuation of cyclosporine.
authors.affiliation: Service d'Hématologie de I'Enfant de Strasbourg, France.
authors.forename: P
authors.initials: P
authors.lastname: Lutz
authors.forename: I
authors.initials: I
authors.lastname: Zix-Kieffer
authors.forename: G
authors.initials: G
authors.lastname: Souillet
authors.forename: Y
authors.initials: Y
authors.lastname: Bertrand
authors.forename: C
authors.initials: C
authors.lastname: Dhooge
authors.forename: C
authors.initials: C
authors.lastname: Rubie
authors.forename: F
authors.initials: F
authors.lastname: Mazingue
authors.forename: F
authors.initials: F
authors.lastname: Marguerite
authors.forename: F
authors.initials: F
authors.lastname: Machinaud-Lacroix
authors.forename: X
authors.initials: X
authors.lastname: Rialland
authors.forename: E
authors.initials: E
authors.lastname: Plouvier
authors.forename: C
authors.initials: C
authors.lastname: Behar
authors.forename: E
authors.initials: E
authors.lastname: Vilmer
authors.forename: N
authors.initials: N
authors.lastname: Philippe
authors.forename: J
authors.initials: J
authors.lastname: Otten
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007155:Immunologic Factors / Q000627:therapeutic use; D007223:Infant; D007372:Interferons / Q000627:therapeutic use; D015474:Isotretinoin / Q000627:therapeutic use; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D015993:Life Tables; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D012074:Remission Induction; D012189:Retrospective Studies; D013156:Splenectomy; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D014916:Whole-Body Irradiation
chemical_list: D007155:Immunologic Factors; D003561:Cytarabine; D005047:Etoposide; D007372:Interferons; D015122:Mercaptopurine; D015474:Isotretinoin; D006918:Hydroxyurea